ISSN: 1305-385X
Hakkında: Özel sayılar şeklinde yayınlanır.
|
|
|
Use Of Glycoprotein Iib/iiia Inhibitors In Unstable Angina Pectoris
Dr. Ferit AKGÜL,a Dr. Ergün SEYFELİ,a Dr. Fatih YALÇINa
aKardiyoloji AD, Mustafa Kemal Üniversitesi Tayfur Ata Sökmen Tıp Fakültesi, HATAY
Unstable angina pectoris (UAP) represents a clinical state that fall between stable angina and acute myocardial infarction. Plaque rupture and thrombus formation are key events in the pathogenesis of UAP. The glycoprotein (GP) IIb/IIIa is a receptor on the platelet membrane mediates platelet binding in the final common pathway of platelet aggregation. GP IIb/IIIa antagonists inhibit platelet aggregation, and so inhibiting thrombus formation. Treatment with GP IIb/IIIa inhibitors has been shown to improve clinical outcomes in patient who underwent percutaneous coronary intervention (PCI). The benefits of GP IIb/IIIa antagonists are less substantial in UAP patients who treated medically. These agents seem most useful in high-risk patients with unstable coronary syndromes especially in the presence of co-morbidities such as diabetes and increased troponin levels. Major bleeding and thrombocytopenia risk increases after the use of some GP IIb/IIIa receptor antagonists. The bleeding risk may be minimized by reduction and weight-adjustment of concomitant heparin dosing.Keywords: Angina, unstable; platelet glycoprotein GPIIb-IIIa complexTurkiye Klinikleri J Int Med Sci 2007, 3(15):78-86
|
|
|
|
|
